Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, 52-Week Extension Study Assessing XP13512 Safety and Efficacy in Patients With Restless Legs Syndrome.

NCT00333359 is registered in ClinicalTrials.gov with XenoPort, Inc. as lead sponsor.

NCT NCT00333359
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00333359 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, 52-Week Extension Study Assessing XP13512 Safety and Efficacy in Patients With Restless Legs Syndrome.
Lead sponsor
XenoPort, Inc.
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2006
Completion date
December 31, 2008
Enrollment
581 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

restless legs syndrome